These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 14967459)

  • 1. Combining EGFR inhibitors with radiation or chemotherapy: will preclinical studies predict clinical results?
    Harari PM; Huang SM
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):976-83. PubMed ID: 14967459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanisms of disease: Radiosensitization by epidermal growth factor receptor inhibitors.
    Sartor CI
    Nat Clin Pract Oncol; 2004 Dec; 1(2):80-7. PubMed ID: 16264825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted therapies for non-small-cell lung cancer: biology, rationale, and preclinical results from a radiation oncology perspective.
    Raben D; Helfrich B; Bunn PA
    Int J Radiat Oncol Biol Phys; 2004; 59(2 Suppl):27-38. PubMed ID: 15142632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EGFR inhibitor-mediated apoptosis in solid tumors.
    Goel S; Hidalgo M; Perez-Soler R
    J Exp Ther Oncol; 2007; 6(4):305-20. PubMed ID: 18038764
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biology of interactions: antiepidermal growth factor receptor agents.
    Harari PM; Allen GW; Bonner JA
    J Clin Oncol; 2007 Sep; 25(26):4057-65. PubMed ID: 17827454
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EGFR-targeted anti-cancer drugs in radiotherapy: preclinical evaluation of mechanisms.
    Baumann M; Krause M; Dikomey E; Dittmann K; Dörr W; Kasten-Pisula U; Rodemann HP
    Radiother Oncol; 2007 Jun; 83(3):238-48. PubMed ID: 17502118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents.
    Tabernero J
    Mol Cancer Res; 2007 Mar; 5(3):203-20. PubMed ID: 17374728
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical biomarkers of kinase activity: examples from EGFR inhibition trials.
    Krause M; Baumann M
    Cancer Metastasis Rev; 2008 Sep; 27(3):387-402. PubMed ID: 18427731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intrinsic and acquired resistance to EGFR inhibitors in human cancer therapy.
    Bianco R; Troiani T; Tortora G; Ciardiello F
    Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S159-71. PubMed ID: 16113092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of the epidermal growth factor receptor and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based chemotherapy: a report from the Radiation Therapy Oncology Group.
    Chakravarti A; Winter K; Wu CL; Kaufman D; Hammond E; Parliament M; Tester W; Hagan M; Grignon D; Heney N; Pollack A; Sandler H; Shipley W
    Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):309-17. PubMed ID: 15890569
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased risk of high-grade dermatologic toxicities with radiation plus epidermal growth factor receptor inhibitor therapy.
    Tejwani A; Wu S; Jia Y; Agulnik M; Millender L; Lacouture ME
    Cancer; 2009 Mar; 115(6):1286-99. PubMed ID: 19170238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted therapies in combination with chemotherapy in non-small cell lung cancer.
    Johnson DH
    Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4451s-4457s. PubMed ID: 16857827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidermal growth factor receptor inhibitors in development for the treatment of non-small cell lung cancer.
    Heymach JV; Nilsson M; Blumenschein G; Papadimitrakopoulou V; Herbst R
    Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4441s-4445s. PubMed ID: 16857825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progress and challenges in the identification of biomarkers for EGFR and VEGFR targeting anticancer agents.
    Le Tourneau C; Vidal L; Siu LL
    Drug Resist Updat; 2008 Jun; 11(3):99-109. PubMed ID: 18515176
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Signaling through the epidermal growth factor receptor during the development of malignancy.
    Grandis JR; Sok JC
    Pharmacol Ther; 2004 Apr; 102(1):37-46. PubMed ID: 15056497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ongoing first-line studies of epidermal growth factor receptor tyrosine kinase inhibitors in select patient populations.
    Jänne PA
    Semin Oncol; 2005 Dec; 32(6 Suppl 10):S9-15. PubMed ID: 16459174
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted therapies and radiation for the treatment of head and neck cancer: are we making progress?
    Raben D; Bianco C; Milas L; Ang KK
    Semin Radiat Oncol; 2004 Apr; 14(2):139-52. PubMed ID: 15095260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidermal growth factor receptor biology in head and neck cancer.
    Kalyankrishna S; Grandis JR
    J Clin Oncol; 2006 Jun; 24(17):2666-72. PubMed ID: 16763281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
    Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
    Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of epidermal growth factor receptor expression in patients with advanced stage nasopharyngeal carcinoma treated with induction chemotherapy and radiotherapy.
    Chua DT; Nicholls JM; Sham JS; Au GK
    Int J Radiat Oncol Biol Phys; 2004 May; 59(1):11-20. PubMed ID: 15093894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.